Theophylline therapy inhibits neutrophil and mononuclear cell chemotaxis from chronic asthmatic children.
1. Theophylline is commonly used to relieve symptoms of chronic asthma. Since neutrophil and mononuclear cell activation are associated with late phase asthmatic reactions, effects of theophylline on these cells may be of importance. 2. In the present investigation we compared neutrophil and mononuclear cell chemotaxis from chronic asthmatic children during and after theophylline therapy. 3. Thirty patients were recruited for the study. Each patient received theophylline orally for 10 days. The theophylline dose was 20 mg kg-1 day-1 given in four divided doses. On the tenth day, blood was collected into heparinized (100 u ml-1) and siliconized tubes 2 h after the last theophylline dose for chemotactic assays, cAMP and theophylline plasma determinations. When clinical conditions allowed, theophylline was discontinued for 7 days and the chemotactic assays, cAMP and theophylline plasma concentrations repeated. Serum complement and IgE levels were also determined. 4. Theophylline therapy clearly inhibited both spontaneous and stimulated neutrophil and mononuclear cell chemotaxis. Twenty-seven patients had therapeutic plasma concentrations of theophylline (5-20 micrograms ml-1). Discontinuation of theophylline therapy caused a significant decrease in plasma cAMP levels (44 and 31 pmol ml-1 respectively during and after treatment, n = 30, P less than 0.001). 5. The inhibition of neutrophil and mononuclear cell migration by theophylline therapy in chronic asthmatic children may be beneficial for the control of the inflammatory response observed in these patients.
Condino-Neto
A
A
Department of Pediatrics, Faculty of Medical Sciences, UNICAMP, SP, Brazil.
Vilela
M M
MM
Cambiucci
E C
EC
Ribeiro
J D
JD
Guglielmi
A A
AA
Magna
L A
LA
De Nucci
G
G
D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D002648:Child; D003176:Complement C3 / Q000032:analysis; D003181:Complement C4 / Q000032:analysis; D000242:Cyclic AMP / Q000097:blood; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D007963:Leukocytes, Mononuclear / Q000187:drug effects*; D008297:Male; D009504:Neutrophils / Q000187:drug effects*; D013806:Theophylline / Q000494:pharmacology* / Q000627:therapeutic use
D003176:Complement C3; D003181:Complement C4; D007073:Immunoglobulin E; D013806:Theophylline; D000242:Cyclic AMP